RxDoctor Payments Data

Jennifer Francyk, PA

Physician Assistant · Phoenix, AZNPI 1649421306

Payments from drug & device makers

$11,534in general payments, 2019–2025

Across 579 payments — averaging $19.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • AstraZeneca$847
  • Amgen$813
  • Lilly USA, LLC$684
  • GSK$462
  • plus $5K from 43 others

What the payments were for

  • Food & beverage$11,40299%
  • Education$1311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,534 in reported general payments places this provider in the 95th percentile of 2,888 physician assistant providers in Arizona.

See all physician assistant providers in Arizona

Medicare billing

Part B allowed, 2024
$1,827
Medicare patients
18
Services billed
108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide109$126,814
OzempicSemaglutide26$31,700
Valganciclovir Hcl15$2,674
ProgesteroneProgesterone, Micronized47$1,973
ValacyclovirValacyclovir Hcl31$1,355
Bupropion Hcl SrBupropion Hcl36$1,238
Estradiol26$1,132
Liothyronine Sodium29$782
Bupropion XlBupropion Hcl27$757
Minoxidil58$525
Ondansetron OdtOndansetron29$518
Metformin Hcl ErMetformin Hcl99$463
Dutasteride53$452
Levothyroxine Sodium71$353
Famotidine19$203

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$684$126,814109 claims
Novo NordiskOzempic$1,505$31,70026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,888 physician assistant providers in Arizona.

Other physician assistant in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →